Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.

Study shows COVID leaves markers of brain damage in blood

A new report published in Open Forum on Infectious Diseases demonstrates that, despite the proven effectiveness of Paxlovid and molnupiravir against severe outcomes of COVID-19, adoption of these two antivirals remains low among Americans with COVID.

The report focused on antiviral use among vaccinated Americans who contracted COVID-19 between December 2021 and October 2022. Oral absorption of nirmatrelvir/ritonavir (NMV/r or Paxlovid) and molnupiravir ( MOV) increased as the study period progressed, but was low overall. .

Paxlovid absorption was 13.6% (95% confidence interval (CI), 11.9% to 15.2%) among 1,594 participants and MOV absorption was 1.4% (CI at 95%, 0.8% to 2.1%) among 1,398 participants. Paxlovid usage has increased over time, from 1.9% from December 2021 to March 2022 to 25.3% between August and October 2022.

During the study, most participants were eligible for antiviral use (NMV/r: 85%; MOV: 84%), with highest use among those 65 years and older. Paxlovid use was 30.2% (95% CI, 22.2% to 38.2%) among adults 65 years and older, and was also higher among those who self-reported a history of COVID long.

A number of factors may contribute to low use of antivirals among these, including low awareness of antivirals.

“There are a number of factors that may contribute to low use of antivirals among these, including low knowledge of antivirals, health care disparities, and barriers to accessing health care and services. prescriptions,” the authors said. “A population-based study in New York found that 44% of adults were unaware of antiviral drugs.”

Gn En gealth

Back to top button